JP2015518862A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015518862A5 JP2015518862A5 JP2015513962A JP2015513962A JP2015518862A5 JP 2015518862 A5 JP2015518862 A5 JP 2015518862A5 JP 2015513962 A JP2015513962 A JP 2015513962A JP 2015513962 A JP2015513962 A JP 2015513962A JP 2015518862 A5 JP2015518862 A5 JP 2015518862A5
- Authority
- JP
- Japan
- Prior art keywords
- curcumin
- complex
- phospholipid
- oil
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 287
- 235000012754 curcumin Nutrition 0.000 claims description 143
- 239000004148 curcumin Substances 0.000 claims description 143
- 229940109262 curcumin Drugs 0.000 claims description 143
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 143
- 150000003904 phospholipids Chemical class 0.000 claims description 91
- 239000000203 mixture Substances 0.000 claims description 62
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 39
- 239000000787 lecithin Substances 0.000 claims description 39
- 235000010445 lecithin Nutrition 0.000 claims description 39
- 229940067606 lecithin Drugs 0.000 claims description 39
- 239000002904 solvent Substances 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 25
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 13
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims description 9
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 8
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 8
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 8
- 235000005875 quercetin Nutrition 0.000 claims description 8
- 229960001285 quercetin Drugs 0.000 claims description 8
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 7
- 235000019100 piperine Nutrition 0.000 claims description 7
- MXXWOMGUGJBKIW-YPCIICBESA-N piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 claims description 7
- 229940075559 piperine Drugs 0.000 claims description 7
- WVWHRXVVAYXKDE-UHFFFAOYSA-N piperine Natural products O=C(C=CC=Cc1ccc2OCOc2c1)C3CCCCN3 WVWHRXVVAYXKDE-UHFFFAOYSA-N 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 6
- 239000003921 oil Substances 0.000 description 85
- 235000019198 oils Nutrition 0.000 description 85
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 60
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 46
- 239000000243 solution Substances 0.000 description 34
- 235000014113 dietary fatty acids Nutrition 0.000 description 24
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 24
- 229930195729 fatty acid Natural products 0.000 description 24
- 239000000194 fatty acid Substances 0.000 description 24
- 150000004665 fatty acids Chemical class 0.000 description 24
- 229940090949 docosahexaenoic acid Drugs 0.000 description 23
- 241000237536 Mytilus edulis Species 0.000 description 15
- 235000020638 mussel Nutrition 0.000 description 15
- 238000009835 boiling Methods 0.000 description 13
- 239000003085 diluting agent Substances 0.000 description 13
- 238000001704 evaporation Methods 0.000 description 13
- 230000008020 evaporation Effects 0.000 description 13
- 230000008901 benefit Effects 0.000 description 10
- 238000010992 reflux Methods 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 238000010521 absorption reaction Methods 0.000 description 9
- 239000012530 fluid Substances 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 238000005538 encapsulation Methods 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 230000002195 synergetic effect Effects 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 229940012843 omega-3 fatty acid Drugs 0.000 description 6
- 239000006014 omega-3 oil Substances 0.000 description 6
- 238000013459 approach Methods 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 208000019622 heart disease Diseases 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 150000003905 phosphatidylinositols Chemical class 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229940106189 ceramide Drugs 0.000 description 3
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 3
- 230000009918 complex formation Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000019688 fish Nutrition 0.000 description 3
- 229940106134 krill oil Drugs 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 235000020778 linoleic acid Nutrition 0.000 description 3
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000003586 protic polar solvent Substances 0.000 description 3
- 229940119224 salmon oil Drugs 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000238366 Cephalopoda Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 241000238424 Crustacea Species 0.000 description 2
- 229930153442 Curcuminoid Natural products 0.000 description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 238000010668 complexation reaction Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 229940060184 oil ingredients Drugs 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 150000003907 phosphatidylinositol monophosphates Chemical class 0.000 description 2
- -1 phosphatidylinositol triphosphate Chemical class 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229940083466 soybean lecithin Drugs 0.000 description 2
- 239000008347 soybean phospholipid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940005741 sunflower lecithin Drugs 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- UEPVWRDHSPMIAZ-IZTHOABVSA-N (1e,4z,6e)-5-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)hepta-1,4,6-trien-3-one Chemical compound C1=C(O)C(OC)=CC(\C=C\C(\O)=C\C(=O)\C=C\C=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-IZTHOABVSA-N 0.000 description 1
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- HJTVQHVGMGKONQ-LUZURFALSA-N Curcumin II Natural products C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=CC(O)=CC=2)=C1 HJTVQHVGMGKONQ-LUZURFALSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 101150037263 PIP2 gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 101100262439 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) UBA2 gene Proteins 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- JYTVKRNTTALBBZ-UHFFFAOYSA-N bis demethoxycurcumin Natural products C1=CC(O)=CC=C1C=CC(=O)CC(=O)C=CC1=CC=CC(O)=C1 JYTVKRNTTALBBZ-UHFFFAOYSA-N 0.000 description 1
- PREBVFJICNPEKM-YDWXAUTNSA-N bisdemethoxycurcumin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)CC(=O)\C=C\C1=CC=C(O)C=C1 PREBVFJICNPEKM-YDWXAUTNSA-N 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 231100000762 chronic effect Toxicity 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 235000021438 curry Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- NMRUIRRIQNAQEB-UHFFFAOYSA-N demethoxycurcumin Natural products OC(=CC(C=CC1=CC(=C(C=C1)O)OC)=O)C=CC1=CC=C(C=C1)O NMRUIRRIQNAQEB-UHFFFAOYSA-N 0.000 description 1
- YXAKCQIIROBKOP-UHFFFAOYSA-N di-p-hydroxycinnamoylmethane Natural products C=1C=C(O)C=CC=1C=CC(=O)C=C(O)C=CC1=CC=C(O)C=C1 YXAKCQIIROBKOP-UHFFFAOYSA-N 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- UEPVWRDHSPMIAZ-UHFFFAOYSA-N p-hydroxycinnamoyl feruloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(O)=CC(=O)C=CC=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-UHFFFAOYSA-N 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229950004354 phosphorylcholine Drugs 0.000 description 1
- 150000003019 phosphosphingolipids Chemical class 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Images
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ600146 | 2012-05-22 | ||
| NZ60014612 | 2012-05-22 | ||
| PCT/NZ2013/000086 WO2013176555A1 (en) | 2012-05-22 | 2013-05-22 | Improved complexes and compositions containing curcumin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015518862A JP2015518862A (ja) | 2015-07-06 |
| JP2015518862A5 true JP2015518862A5 (enExample) | 2016-01-14 |
| JP6211603B2 JP6211603B2 (ja) | 2017-10-11 |
Family
ID=49624145
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015513962A Expired - Fee Related JP6211603B2 (ja) | 2012-05-22 | 2013-05-22 | クルクミンを含有する改善された複合体および組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20150104503A1 (enExample) |
| EP (2) | EP3666265A1 (enExample) |
| JP (1) | JP6211603B2 (enExample) |
| KR (2) | KR20190090075A (enExample) |
| CN (3) | CN110870857A (enExample) |
| AU (1) | AU2013264466B2 (enExample) |
| CA (1) | CA2910089A1 (enExample) |
| HK (1) | HK1208375A1 (enExample) |
| IN (1) | IN2014MN02552A (enExample) |
| WO (1) | WO2013176555A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102013220974A1 (de) * | 2013-10-16 | 2015-04-16 | Briu Gmbh | Zusammensetzung zur oralen Administration von Curcumin |
| JP6987528B2 (ja) * | 2017-05-12 | 2022-01-05 | 小林製薬株式会社 | クルクミノイド含有錠剤 |
| CN109846865B (zh) * | 2018-12-26 | 2022-03-25 | 晨光生物科技集团股份有限公司 | 一种姜黄素制剂及其制备方法 |
| CN109589410B (zh) * | 2018-12-26 | 2022-02-01 | 晨光生物科技集团股份有限公司 | 一种姜黄素制剂及其制备方法 |
| KR102169710B1 (ko) * | 2020-01-08 | 2020-10-26 | 제주대학교 산학협력단 | 커큐민 나노스피어, 그 제조방법 및 이의 용도 |
| WO2021203878A1 (zh) * | 2020-04-10 | 2021-10-14 | 上海利统生化制品有限公司 | 一种缓解视疲劳的可食用组合物 |
| US12357665B2 (en) * | 2020-09-11 | 2025-07-15 | Tzung-Yan | Pharmaceutical compositions and uses thereof in treating muscle atrophy |
| EP4251136A1 (en) * | 2020-11-24 | 2023-10-04 | Specchiasol S.r.l. | Formulation for oral administration of active compounds with low bioavailability and corresponding production method |
| WO2023055005A1 (ko) * | 2021-09-28 | 2023-04-06 | (주) 바이노텍 | 입자 표면이 개질된 커큐민 나노 입자 복합체 및 이의 제조 방법 |
| WO2023119230A1 (en) | 2021-12-22 | 2023-06-29 | L'oreal | Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use |
| WO2023161955A1 (en) * | 2022-02-28 | 2023-08-31 | Gidaa Life Sciences Pvt. Ltd. | A phytoactive encapsulated formulation for neurodegenerative diseases |
| CN115813780B (zh) * | 2022-03-30 | 2024-08-13 | 广东格烯生物科技股份有限公司 | 一种含四氢姜黄素的纳米级祛黄组合物及其制备方法 |
| IT202200025767A1 (it) | 2022-12-15 | 2024-06-15 | Prolabin & Tefarm S R L | Formulazione comprendente polifenoli vanilloidi supportati su solidi lamellari per ridurre i livelli plasmatici di CGRP e sue applicazioni. |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1201149B (it) * | 1987-01-14 | 1989-01-27 | Indena Spa | Complessi di bioflavonoidi con fosfolipidi,loro preparazione,uso e composizioni farmaceutici e cosmetiche |
| CN1283237C (zh) * | 2004-11-22 | 2006-11-08 | 山东大学 | 姜黄素磷脂复合物及其制备方法 |
| US7759325B2 (en) | 2005-04-18 | 2010-07-20 | Sc Dicophar | Use of lecithin as a medication for the treatment of psoriasis |
| WO2007098118A2 (en) * | 2006-02-16 | 2007-08-30 | Byron Robinson Pharmaceutical, Inc. | Antineoplastic and curcumin derivatives and methods of preparation and use |
| PL1993365T3 (pl) * | 2006-03-06 | 2013-10-31 | Univ California | Preparaty z biodostępnych kurkuminoidów do leczenia choroby alzheimera oraz innych zaburzeń powiązanych z wiekiem |
| EP1837030A1 (en) * | 2006-03-09 | 2007-09-26 | INDENA S.p.A. | Phospholipid complexes of curcumin having improved bioavailability |
| AU2007275660B2 (en) * | 2006-07-19 | 2012-08-02 | The Board Of Regents Of The University Of Texas System | Preparations of phospholipids and pharmaceuticals containing 5-amino salicylic acid for the treatment of inflammatory bowel disease |
| IT1395086B1 (it) * | 2009-03-11 | 2012-09-05 | Velleja Res Srl | Composizioni comprendenti curcumina in forma complessata con fosfolipidi e piperina ad azione chemio-sensibilizzante |
-
2013
- 2013-05-22 CA CA2910089A patent/CA2910089A1/en not_active Abandoned
- 2013-05-22 KR KR1020197021718A patent/KR20190090075A/ko not_active Ceased
- 2013-05-22 AU AU2013264466A patent/AU2013264466B2/en not_active Ceased
- 2013-05-22 CN CN201911125449.XA patent/CN110870857A/zh active Pending
- 2013-05-22 WO PCT/NZ2013/000086 patent/WO2013176555A1/en not_active Ceased
- 2013-05-22 JP JP2015513962A patent/JP6211603B2/ja not_active Expired - Fee Related
- 2013-05-22 HK HK15109169.9A patent/HK1208375A1/xx unknown
- 2013-05-22 CN CN202010235467.XA patent/CN111407752A/zh active Pending
- 2013-05-22 EP EP20150592.2A patent/EP3666265A1/en not_active Withdrawn
- 2013-05-22 EP EP13793432.9A patent/EP2852395A4/en not_active Withdrawn
- 2013-05-22 US US14/402,071 patent/US20150104503A1/en not_active Abandoned
- 2013-05-22 KR KR20147036049A patent/KR20150035730A/ko not_active Ceased
- 2013-05-22 CN CN201380038818.6A patent/CN104540515A/zh active Pending
-
2014
- 2014-12-16 IN IN2552MUN2014 patent/IN2014MN02552A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6211603B2 (ja) | クルクミンを含有する改善された複合体および組成物 | |
| JP2015518862A5 (enExample) | ||
| US20070122452A1 (en) | Fat composition | |
| JP2007504197A (ja) | ホスファチジルセリン塩基の生理学的活性組成物 | |
| US20150110866A1 (en) | Complexes and compositions containing curcumin | |
| WO2015121378A1 (en) | Liquid phospholipid-containing compositions for the preparation of pharmaceuticals | |
| JP4913340B2 (ja) | カプセル剤 | |
| US10960016B2 (en) | Capsules containing high doses of krill phospholipids | |
| JP6949670B2 (ja) | 難溶性物質を含有する経口摂取用組成物、難溶性物質の消化管吸収性の向上方法及び難溶性物質を含有する水中油型乳化物の胃内での乳化安定化方法 | |
| NZ610906A (en) | Improved complexes and compositions containing curcumin | |
| EP3206677A1 (en) | Monounsaturated fatty acid compositions and use for treating atherosclerosis | |
| CN103859395A (zh) | 一种高吸收率的辅酶q10的自乳化释药体系及其制备方法及应用 | |
| NZ610906B (en) | Improved complexes and compositions containing curcumin | |
| JP5221114B2 (ja) | ソフトカプセル剤 | |
| JP4969989B2 (ja) | リン脂質組成物およびこれを含有する食品組成物、医薬品組成物、並びにその製造方法 | |
| TW200904456A (en) | Organic compounds | |
| CN106456783A (zh) | 含有欧米茄‑3多不饱和脂肪酸和白藜芦醇的口服均相制剂 | |
| JP2012051945A (ja) | カプセル剤、カプセル剤の製造方法およびカプセル皮膜 | |
| WO2023275190A1 (en) | Soft gel capsule | |
| WO2011124895A2 (en) | Phospholipid-containing pharmaceutical and nutraceutical compositions | |
| KR20250089549A (ko) | 치료 화합물의 전달을 위한 인지질 조성물 | |
| WO2018146060A1 (en) | Long-term efficacy of liver disease treatment with epa and dha |